Junshi's Toripalimab Subcutaneous Injection Application Accepted In China For Bladder Cancer

China’s NMPA accepted Junshi Biosciences’ supplemental new drug application for a subcutaneous formulation of toripalimab combined with disitamab vedotin as a first-line treatment. Acceptance is a regulatory milestone, not an approval; the supplied article text is truncated before the full treatment indication.